Paige
Cancer pathology AI behind the FDA-authorised Paige Prostate, now part of Tempus
Overview
Paige is a New York computational pathology company, spun out of Memorial Sloan Kettering and acquired by Tempus AI in 2025. It sells AI applications that help pathologists detect and grade cancer on digitised slides, led by the FDA-authorised Paige Prostate, plus Paige Predict biomarker estimates and the Virchow and PRISM foundation models for research.
Pricing
Pricing shown for reference only. These figures reflect RECATOOLS research as of 14 Oct 2026 and may be out of date or incomplete. This is not financial or purchasing advice — always confirm the current price on the provider’s official website before making any decision.
- Paige Prostate detection and grading
- Breast cancer identification and classification
- GI tract detection and classification
- PanCancer detection across tissue types
- Foundation model licensing
- PanCancer AI modules
- Custom AI development and regulatory strategy
Use cases
What you can produce with Paige
- Highlighted suspicious regions on digitised prostate biopsy slides (FDA De Novo authorised)
- Detection and grading support for prostate needle biopsies (Paige Prostate Suite)
- Breast, gastrointestinal and PanCancer detection on H&E whole-slide images
- Paige Predict estimates for 123 biomarkers across 16 cancer types, returned with the clinical report
- Virchow foundation model weights for research (Apache 2.0; later models non-commercial)
- FullFocus slide viewing, FDA-cleared with Philips, Leica and Hamamatsu scanners
ASEAN Perspective
Paige in Southeast Asia
Paige holds FDA, CE-IVD, and UKCA authorizations for its prostate cancer AI suite, but no announced regulatory approvals in ASEAN or broader APAC jurisdictions as of mid-2026. Its training dataset spans 45 countries, providing some demographic diversity relevant to Asian populations, though slide representation from Southeast Asia specifically is unconfirmed. The Microsoft Azure cloud infrastructure supporting the platform enables global deployment in principle, which is relevant to Singapore, Australia, and Japan — but commercial rollout in ASEAN markets depends on local health-technology assessment and reimbursement frameworks that have not yet been publicly addressed by Tempus/Paige. ASEAN pathology labs with digital pathology infrastructure and an interest in AI-assisted cancer detection should engage Tempus directly to assess regional availability and compliance pathways.
Paige has the strongest regulatory record in AI pathology: a 2021 FDA De Novo authorisation for Paige Prostate, Breakthrough designations, and CE and UKCA marks across its suites. The evidence deserves careful reading, though. The FDA estimated a 7.3% sensitivity gain per cancer slide and a smaller one per patient, and the widely quoted Yale accuracy figures come from a Paige-funded study.
Under Tempus it is moving towards biomarker prediction and open-source viewing software. Pricing is quoted per deployment, a 30-day trial is offered, and ASEAN hospitals would need local clearance. For research groups, the Virchow models are the accessible entry point.
What we found
Paige is a computational pathology company spun out of Memorial Sloan Kettering Cancer Center in 2017, and since August 2025 part of Tempus AI, which agreed to buy it for $81.25 million, mostly in stock, gaining nearly 7 million digitised slides from 45 countries for its oncology foundation models. Paige's own website still reads as of 2025; product news now comes from Tempus.
Its regulatory landmark is real but narrower than the marketing. On 21 September 2021 the FDA granted Paige Prostate a De Novo authorisation, creating a new device class for software that helps pathologists find suspicious areas on digitised prostate biopsies. Paige calls it the first FDA-approved AI in pathology. The FDA's decision summary estimates that assisted reads improved sensitivity on 7.3% of biopsies containing cancer, and warns that the benefit per patient would likely be substantially lower. A 2021 study of 1,876 Yale biopsy slides reported 97.7% sensitivity and 99.3% specificity; Paige funded it, and Paige employees were among the authors.
Beyond prostate, Paige sells breast, gastrointestinal and PanCancer suites, lists three FDA Breakthrough designations, 13 CE-IVDD and 13 UKCA marks, and offers a 30-day trial of its diagnostic suites. Its FullFocus viewer is FDA-cleared with Philips, Leica and Hamamatsu scanners, and its Alba co-pilot pulls pathology, radiology and patient history into one summary. In January 2026 Tempus launched Paige Predict, which estimates the likelihood of 123 biomarkers across 16 cancer types from a standard H&E slide, trained on data from more than 200,000 patients. In June 2026 Tempus said it would open-source the Paige image-management software, including FullFocus and FullFolio, through a consortium with Yale New Haven Hospital and Memorial Sloan Kettering.
Researchers can request the Virchow foundation model under Apache 2.0, and Virchow2, PRISM and PRISM2 under a non-commercial licence, on Hugging Face. Clinical products are quoted per deployment, and hospitals in ASEAN would need their own national regulatory clearance before clinical use.
Compiled by RECATOOLS from public sources: vendor documentation and pricing, code repositories and published reporting.
Notable facts
- Paige's FDA De Novo authorization in September 2021 was the very first for any AI product in the entire history of digital pathology.
- The Virchow foundation model was trained on 1.5 million MSK slides — the largest pathology training dataset publicly disclosed at the time of its release in 2024.
- Paige was acquired by Tempus for $81.25 million in August 2025 — a valuation representing less than 40% of its total $241M raised, reflecting a tough funding environment for health-tech.
- The company's name is a tribute to James Paget, the 19th-century British surgeon who described several conditions still taught in pathology today.
Frequently asked questions
About this listing
This entry was compiled from publicly available data including Paige's official website, press releases, documentation, and reputable third-party publications. RECATOOLS is not affiliated with Paige unless explicitly stated.
Third-party AI tools update their pricing, features, availability, and policies frequently. Information here may be outdated by the time you read this — we make reasonable efforts to keep listings current, but cannot guarantee absolute accuracy.
For the latest details, please refer to Paige directly →
Spotted something out of date? Suggest an update →
Related reading
Health & Wellness
Brown Fat Linked to Less Diabetes, Heart Disease and Depression in Scans of 101,243 Cancer...
Health & Wellness
Melanoma Immunotherapy Left Half of Patients With Lasting Side Effects. A Study Asks Who.
Health & Wellness
A Drug Aimed at a Weak Point in Some Cancers Shrank Tumours in 7 of 66 Patients
Alternatives to Paige
More in Healthcare
